New PARP Drug ‘Could Benefit Most Ovarian Cancer Patients’
Patients with platinum-sensitive recurrent ovarian cancer, regardless of their BRCA mutation status, showed extended progression-free survival with the new PARP inhibitor niraparib. Medscape Medical News …read more